Welcome to our dedicated page for Cognex SEC filings (Ticker: CGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cognex Corporation (CGNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this industrial machine vision issuer reports its financial and corporate information. Cognex is incorporated in Massachusetts and files under Commission File Number 001-34218, with its common stock listed on NASDAQ under the symbol CGNX.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, where Cognex discusses its machine vision business, risk factors, and financial statements. These filings are important for understanding trends in logistics and factory automation demand, as well as the company’s investment in AI-enabled vision products, as referenced in its public communications.
Investors will also find Form 8-K current reports that Cognex uses to announce material events. Recent 8-K filings include the release of quarterly financial results, dividend declarations, and an audit firm rotation in which the Audit Committee selected KPMG LLP as the independent registered public accounting firm for a future fiscal year, following Grant Thornton LLP. Such filings provide timely insight into corporate actions and governance decisions.
On this page, users can monitor real-time updates from EDGAR, including 8-Ks, 10-Qs, 10-Ks, and other forms that Cognex may file. Stock Titan’s tools offer AI-powered summaries that help explain the contents of lengthy filings, highlight key sections, and clarify technical language around accounting, risk disclosures, and strategic priorities. In addition, Form 4 insider transaction reports, when filed, can be accessed to review share transactions by Cognex officers, directors, or significant shareholders.
By using the CGNX filings page, investors and researchers can quickly move from raw SEC documents to clearer explanations of how Cognex presents its financial condition, machine vision strategy, and corporate developments in official filings.
Sheila Marie DiPalma, Executive Vice President, Employee Services at Cognex Corporation (CGNX), reported open-market dispositions under a Rule 10b5-1 trading plan. On 09/05/2025 she sold 2,002 shares at $45.00, reducing her direct common stock holding to 8,582 shares. On 09/08/2025 she sold 2,000 shares at $45.03, reducing holdings to 6,582 shares. The filing lists substantial outstanding option and restricted stock unit positions exercisable into common stock, totaling tens of thousands of shares across multiple option grants and RSU awards.
Laura A. MacDonald, Vice President and Principal Accounting Officer of Cognex Corporation (CGNX), reported transactions on Form 4 showing an open-market sale and her remaining holdings. On 09/05/2025 she sold 2,666 shares of Cognex common stock at $45 per share pursuant to a Rule 10b5-1 trading plan. After that sale she directly owned 4,593 shares. She also reports 20 shares held by her child, which she disclaims beneficial ownership of except for pecuniary interest.
The filing lists detailed equity compensation holdings: multiple outstanding non-qualified stock options totaling 238,695 underlying shares and restricted stock units totaling 33,914 shares (by schedule), with various exercise prices and expiration dates.
Form 144 notice for Cognex Corp (CGNX): This filing notifies the proposed sale of 4,002 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $177,168.54. The shares represent restricted stock units acquired from the issuer on 02/22/2023 and the filer lists the approximate date of sale as 09/05/2025 on the NASDAQ. The filing reports no securities sold in the past three months for the account and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for Cognex Corp (CGNX) reports a proposed sale of 2,666 shares of Common Stock through broker Robert W Baird & Co., with an aggregate market value of $119,970 and approximate sale date of 09/05/2025 on NASDAQ. The filing shows the 2,666 shares were acquired through three Restricted Stock Unit releases on 02/21/2025, 02/22/2025 and 03/15/2025 totaling 2,666 shares, and fully settled upon vesting. The filing states there were no securities sold in the past three months by the reporting person. Filer contact and issuer identification fields in the notice are present but contain no specific names or CIK values in the provided content.
Matthew Moschner, CEO & President and a director of Cognex Corporation (CGNX), reported equity activity tied to restricted stock units that vested on 08/07/2025. A grant of 3,000 restricted stock units vested on that date, and 881 shares were withheld to satisfy tax-withholding obligations at a reported price of $41.36 per share. The Form 4 shows each RSU converts to one share and explains the vesting schedule for the grant (approximately 20%, 30% and 50% on the first three anniversaries of the grant date). The filing also details the reporting person’s outstanding stock option positions and other RSU balances, including a large option block of 279,070 options at a $27.99 strike, documenting the executive’s continuing equity holdings in the company.